1. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. Issue 1 (3rd May 2021) Authors: Reifsnider, Odette S; Kansal, Anuraag R; Gandhi, Pranav K; Cragin, Lael; Brand, Sarah B; Pfarr, Egon; Fahrbach, Kyle; Ustyugova, Anastasia Journal: BMJ open diabetes research and care Issue: Volume 9:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗